anti-Mycn (MYCN) Antibodies

MYCN is a member of the MYC family and encodes a protein with a basic helix-loop-helix (bHLH) domain. Additionally we are shipping MYCN Kits (8) and MYCN Proteins (7) and many more products for this protein.

Data indicate that inter-play between MYCN and the highly tumorigenic proteins which are upregulated in the malignant IMR-32 neuroblastoma (show ARHGEF16 Antibodies) cells may be fueling their aggressive behavior.

these results suggest that MYCN serves as a prognostic biomarker and therapeutic target of ACR (show ACR Antibodies) for liver cancer stem cell in de novo Hepatocellular carcinoma.

High TrkA (show NTRK1 Antibodies) expression is one of the most powerful predictor of good prognosis in neuroblastoma (show ARHGEF16 Antibodies) and is associated with younger age, lower stage, and absence of MYCN amplification

interactions of NF-kappaB (show NFKB1 Antibodies) and N-myc with GLT-1/EAAT2 (show SLC1A2 Antibodies) promoter sequences was significantly elevated in the ipsi-lateral cortex of both adult and old Traumatic brain injury mice.

we report the isolation and propagation of neuroblastoma (show ARHGEF16 Antibodies) sphere-forming cells with self-renewal and differentiation potential from tumors of the TH-MYCN mouse, an animal model of high-risk neuroblastoma (show ARHGEF16 Antibodies) with MYCN amplification

miR (show MLXIP Antibodies)-34a contributes to the expansion of Myeloid-derived suppressor cells by inhibiting the apoptosis via suppressing the expression of N-myc.

the role of N-myc in mouse lens development, was examined.

Using comparative genomic hybridization, authors found that NCC (show SLC12A3 Antibodies)-derived NBL (show NUMBL Antibodies) tumors in mice acquired copy number gains and losses that are syntenic to those observed in human MYCN-amplified NBL (show NUMBL Antibodies) including 17q gain, 2p gain and loss of 1p36.

a Mycn target gene encoding the miR (show MLXIP Antibodies) cluster miR-17~92, while most retinoblastomas reemerged without clear genetic alterations in either Mycn or known Mycn targets. This Rb/MYCN model recapitulates key genetic driver alterations seen in human retinoblastoma and reveals the emergence of MYCN independence in an initially MYCN-driven tumor.

ALKR1275Q cooperated with MYCN in the development of aggressive NB, possibly by downregulating the expression of ECM (show MMRN1 Antibodies)/BM-associated genes and by conferring malignant potentials to MYCN-expressing cells.

The authors demonstrate in zebrafish that nf1 (show NF1 Antibodies) loss leads to aberrant activation of RAS (show RAB1A Antibodies) signaling in MYCN-induced neuroblastomas that arise in these precursors, and that the GTPase-activating protein (GAP)-related domain (GRD) is sufficient to suppress the acceleration of neuroblastoma (show ARHGEF16 Antibodies) in nf1 (show NF1 Antibodies)-deficient fish, but not the hypertrophy of sympathoadrenal cells in nf1 (show NF1 Antibodies) mutant embryos.

At somitogenesis stages, nmyc1 expression was detected in the retina, midbrain, posterior hindbrain and presumptive spinal cord. It was also transcribed in the endoderm and its derivatives as well as in branchial arches.

MYCN Antigen Profile

Protein Summary

This gene is a member of the MYC family and encodes a protein with a basic helix-loop-helix (bHLH) domain. This protein is located in the nucleus and must dimerize with another bHLH protein in order to bind DNA. Amplification of this gene is associated with a variety of tumors, most notably neuroblastomas.